Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Plecanatide is a synthetic 16-amino acid peptide structurally related to human uroguanylin and functions as a guanylate cyclase-C (GC-C) agonist. It is approved for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) in adults. Plecanatide acts locally on the luminal surface of intestinal epithelial cells, activating GC-C receptors in a pH-sensitive manner. This activation increases intracellular cyclic guanosine monophosphate (cGMP), which stimulates secretion of chloride and bicarbonate into the intestinal lumen via activation of the cystic fibrosis transmembrane conductance regulator (CFTR). The resulting increase in intestinal fluid softens stool and accelerates transit through the gastrointestinal tract. Plecanatide is minimally absorbed systemically, with its effects localized to the GI tract.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on plecanatide.